MDL | MFCD00867219 |
---|---|
Molecular Weight | 269.38 |
Molecular Formula | C14H27N3O2 |
SMILES | O=C(NCCN(C(C)C)C(C)C)CN1C(CCC1)=O |
Pramiracetam is a nootropic drug derived from piracetam, and is more potent. Pramiracetam reportedly improved cognitive deficits associated with traumatic brain injuries. IC50 Value: Target: in vitro: Pramiracetam sulfate did not exhibit any affinity in vitro for dopaminergic , GABAergic, serotoninergic, adrenergic, muscarinic, adenosine (IC50 > 10 uM), and benzodiazepine receptors (IC50 > 1 uM) binding sites [1]. in vivo: In a double-blind, randomized design, two groups of six subjects each received alternating placebo and single 400, 800, 1,200, and 1,600 mg oral doses of pramiracetam after an overnight fast. Mean (+/- SD) peak plasma concentrations of the four dose groups (2.71 +/- 0.54, 5.40 +/- 1.34, 6.13 +/- 0.71, 8.98 +/- 0.71 micrograms/mL) were attained between two to three hours following drug administration [2]. Two doses of pramiracetam (7.5 mg/kg and 15 mg/kg) were administered daily prior to testing for 7 weeks in a 16-arm radial maze in which nine arms were baited with food [3].
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : ≥ 100 mg/mL ( 371.22 mM )
H 2 O : ≥ 100 mg/mL ( 371.22 mM )
* "≥" means soluble, but saturation unknown.
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 3.7122 mL | 18.5611 mL | 37.1223 mL |
5 mM | 0.7424 mL | 3.7122 mL | 7.4245 mL |
10 mM | 0.3712 mL | 1.8561 mL | 3.7122 mL |
Add each solvent one by one: PBS
Solubility: 12.5 mg/mL (46.40 mM); Clear solution; Need ultrasonic
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (9.28 mM); Clear solution
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (9.28 mM); Clear solution